The earnings call reflects a mixed sentiment. While there are positive elements like reduced expenses and potential for broader label approval, significant concerns remain. Financial constraints have slowed trial progress, impacting timelines. The company's dependence on partnerships and equity financing poses risks of dilution. Furthermore, competitive pressures and operational risks in trial execution are notable challenges. The Q&A did not alleviate these concerns, as management's responses were often vague. Given these factors, the stock price is likely to remain stable, resulting in a neutral prediction for the next two weeks.